Michelle Ottey, PhD

MassBio CEO & President Kendalle Burlin O'Connell, Esq. recently spoke with Adil Ali, MD and Onyx about representing the world's most consequential life sciences ecosystem, MassBio's Vision 2030 strategic roadmap, programs like #MassBioDrive and BioversityMA, and more. Onyx's in-depth report, Vital Signs: Future of Healthcare, will appear in Fortune magazine in December ahead of JPM Week. 🔗: https://lnkd.in/eVkggiwv

35

1 Comment

The Post-BioHealth Capital Region Week BHI E-Newsletter is live! This week we have stories including: 🌟 Leadership and Innovation at BioHealth Capital Region Week: Industry leaders, including Maryland Gov. Wes Moore and Virginia Governor Glenn Youngkin gather for impactful keynotes, panels, discussions and networking opportunities. 🎉 Linshom Medical, Inc. Wins Crab Trap Competition: The TEDCO-backed company secures the title with its FDA-cleared wearable respiratory monitoring device. 🏅 Virginia Governor Recognized: Glenn Youngkin receives BIO’s 2024 Governor of the Year Award for his leadership in strengthening the state's biotechnology sector. 🌍 Immobazyme Competes in Crab Trap: The South African biotech company presents its innovative solutions for diabetic foot ulcers at the competition. h/t TASK 🚀 Advanced Research Projects Agency for Health (ARPA-H) Launches Emerging Health Innovators Initiative: This program aims to increase access to government research funding for early career researchers. 🏥 Children's National Hospital Innovation District Partners with BARDA: A new hub will focus on developing solutions for pediatric health emergencies. 🔍 USP Seeks Expert Volunteers: The US Pharmacopeia calls for professionals to contribute to its mission of ensuring the quality of healthcare products. 💰 TEDCO Invests in CarrTech Corporation, a life sciences company working to support patients and healthcare providers. The Builder Fund is part of TEDCO’s Social Impact Funds, an umbrella of funds designed to support underserved founders and communities. 📈 NIH Establishes Pandemic Preparedness Network: The agency plans up to $100 million annually for research on new treatments and vaccines. 💉 AstraZeneca’s FluMist Approved for Self-Administration: The needle-free nasal spray vaccine is now available for self-administration in eligible age groups. 💻 Astellas Pharma Announces FDA Listing of DIGITIVA™: The digital health solution for heart failure management is classified as a Class I Software as a Medical Device. 📅 Activation Capital Launches Start-the-Journey Program: The new pre-accelerator supports early-stage biotech entrepreneurs with essential tools and knowledge. 🌱 Maryland Stem Cell Research Fund (MSCRF) Awards Grants: Approximately $4.5 million is allocated to advance stem cell research and innovation. all this and more by visiting https://lnkd.in/g2Tha_83

7

CIC (Cambridge Innovation Center), a global leader in building and operating innovation communities, and Persephoni BioPartners, a strategic advisory and Biotech venture studio firm, are excited to announce a strategic partnership built around CIC Philadelphia’s location in uCity Square to drive growth and development of early-stage biotech companies in Philadelphia. “We are incredibly excited to call CIC our home for our Philadelphia operations. Their state of the art facilities will enable our current portfolio companies to accelerate their research and development as we prepare for clinical advancement. We aim to serve across the ecosystem and facilitate cross organizational and institutional collaborations to serve the amazing technologies housed within Philadelphia,” said Hilary Schultz, CEO of Persephoni BioPartners Persephoni has an office on the 7th floor of CIC Philadelphia at 3675 Market Street in the uCity Square Knowledge Community, where it will serve as a landing pad for the companies in its venture studio program. It will also open its doors to existing CIC members, offering advisory services ranging from startup incorporation and capitalization table structure, strategic planning, regulatory strategy, capital raise, and business development to support strategic partnerships. Read more on the CIC Blog! https://lnkd.in/gVxqqmHW

4

1 Comment

MassBioDrive harnesses the power of MassBio’s global life sciences network to help new founders launch their biotech startups. We announced our #MassBioDrive Spring 2024 Cohort back in March, and as we near the end of the eight-week program, we are highlighting our five emerging biotech companies chosen to participate. Today, please meet DoriNano! Q: Tell us about your company and what you’re developing. What are you most excited about? A: DoriNano, a Harvard spinoff, pioneers the use of DNA origami nanoparticles as a transformative delivery platform for combination immunotherapies, offering precise cellular targeting and minimal effective doses of cargo for treating serious diseases. Our mission is to develop safe, effective, and affordable combination nanomedicines that overcome past limitations in nanoparticle-based therapeutics. We are particularly excited about the multifaceted potential of DNA origami nanoparticles, which have the potential to revolutionize the nanotechnology delivery landscape. Q: What advice do you have for other biotech companies just getting started? A: Starting a biotech company requires resilience, a willingness to learn, and openness to suggestions. Every challenge presents an opportunity for growth. Embrace the journey, endure sacrifice, minimize complaints, learn from setbacks, and move forward. Building the right team is the key and most challenging sector. Surround yourself with dedicated individuals who share your vision.  Q: What has been most impactful or surprising to you since joining the MassBioDrive program? A: The MassBioDrive program's structured approach, coupled with the dedication of organizers and mentors, has been very impactful. The informative working sessions cover vital aspects of company launch, regulatory compliance, legal considerations, CMC considerations, investment strategies and pharma partnering. As a scientist-turned-entrepreneur, these resources have been invaluable, providing comprehensive guidance tailored to our needs. The interactive Q&A sessions during both mentor sessions and working sessions have deepened our comprehension and helped address questions regarding the company’s development. Learn more about DoriNano: https://lnkd.in/eXJ7PQ_X Learn more about MassBioDrive: https://lnkd.in/eAEMRZ-b Yang (Claire) Zeng

21

MassBioDrive harnesses the power of MassBio’s global life sciences network to help new founders launch their biotech startups. We announced our #MassBioDrive Spring 2024 Cohort back in March, and as we near the end of the eight-week program, we are highlighting our five emerging biotech companies chosen to participate. Today, please meet Nucyrna Therapeutics! Q: Tell us about your company and what you’re developing. What are you most excited about? A: Nucyrna Therapeutics aims to redefine RNA-targeting therapeutics by co-targeting nuclear and cytoplasmic RNAs. Nucyrna’s oligonucleotide platform enables a superior therapeutics index for single RNA silencing and can serve as a dual-RNA targeting platform. With our lead programs targeting ALS, we are working to address the huge unmet medical needs in CNS disorders in our rapid aging society. I’m most excited about developing disease-modifying therapies for these patients. Q: What advice do you have for other biotech companies just getting started? A: It’s never too early to talk to advisors such as serial entrepreneurs for advice. MassBioDrive is an amazing mentorship program helping entrepreneurs figure out challenges at the early stage. Q: What has been most impactful or surprising to you since joining the MassBioDrive program? A: The most impactful thing is we have decided our leading two programs based on our oligonucleotide platform technology with the guidance from MassBioDrive program mentors. Learn more about Nucyrna Therapeutics: https://www.nucyrnatx.com/ Learn more about MassBioDrive: https://lnkd.in/eAEMRZ-b Damon (Feng) Wang, PhD

30

MassBioDrive harnesses the power of MassBio’s global life sciences network to help new founders launch their biotech startups. We announced our #MassBioDrive Spring 2024 Cohort back in March, and as we near the end of the eight-week program, we are highlighting our five emerging biotech companies chosen to participate. Today, please meet Anita Scheuber and Hestia Therapeutics! Q: Tell us about your company and what you’re developing. What are you most excited about? A: At Hestia, we are developing the aNKor platform of tri-specific, tri-funtional immunocytokines that engage the adaptive AND innate immune system to very effectively attack cancer cells. Our approach is a targeted delivery of potent cytokines into the tumor microenvironment that is safer for patients compared to naked cytokines. Q: What advice do you have for other biotech companies just getting started? A: Surround yourself with a diverse group of people that bring industry relevant expertise to complement your own. Q: What has been most impactful or surprising to you since joining the MassBioDrive program? A: The Biotech hub in the Boston area remains strong, innovative and daring - it is just fantastic to learn through the MassBioDrive program that the immense resources, support and entrepreneurship still exists. It is truly inspiring and humbling to receive all that encouragement. Learn more about Hestia Therapeutics: https://hestiatx.com/ Learn more about MassBioDrive: https://lnkd.in/eAEMRZ-b

17

🌟 Philadelphia is making headlines in the biotech world! At the 3rd Annual Philly Builds Bio+ Symposium, Rebecca L Grant, DVM Grant, Senior Director of Life Science #Innovation, unveiled a powerful outlook for the region's life sciences sector. 📊 🔬 "Philadelphia is not just following trends; we are setting the pace for innovation," Grant said. With over 13,000 life science professionals and significant NIH funding, the city is poised for groundbreaking advancements. 📖 Read more about how #Philadelphia is shaping the future of biotech! 👉 #PhillyBiotech #Innovation #LifeSciences #Healthcare #BioHealthCapital #ResearchAndDevelopment

17

1 Comment

🎯 Don’t Michael Lebowitz’s Expert Roundtable at Immunotherapies Xchange Maryland 2024! 🎯 We're thrilled to announce that Michael Lebowitz, Ph.D., VP of Research at Athanor Biosciences, will be leading an exciting roundtable discussion on: Topic: Modulating the Immune Response to Prevent Immunogenicity/Anti-Drug Antibodies 💡 Key discussion points: 🔬 Can we prevent anti-drug antibodies by down-regulating immune responses? 🎯 Antigen-specific vs. systemic immune responses—what’s more effective? ⚙️ Should we target immune responses separately or together? 🧠 Key lessons from cancer and autoimmune immunotherapies. This is your opportunity to engage in insightful discussions with a leading expert and network with industry peers! 🌟 📅 Date: October 29, 2024 🕒 Time: 3:40 PM - 4:40 PM 📍 Location: College Park Marriott Hotel, Maryland 📝 Register today to reserve your seat! https://lnkd.in/evBQ5QQt 💊 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #Immunotherapies #Biotech #Pharma #Immunology #CancerResearch #Immunogenicity #AntibodyTherapy #ClinicalDevelopment #DrugDevelopment #ImmunotherapyInnovation #HealthcareLeadership #MedicalResearch #Biopharma #Networking #Innovation #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

4

MassBioDrive harnesses the power of MassBio’s global life sciences network to help new founders launch their biotech startups. We announced our #MassBioDrive Fall 2024 Cohort last month, and are highlighting our five emerging biotech companies chosen to participate. Today, please meet RedPoint Oncology, Inc! Q: Tell us about your company and what you’re developing. What are you most excited about? A: At RedPoint, we are committed to overcoming therapy-resistant cancers by developing next-generation payloads for targeted therapies. Therapy resistance is responsible for more than 90% of cancer-related deaths, and our payloads are specifically designed to induce a form of cell death that these difficult-to-treat cancer cells are particularly vulnerable to. We are particularly excited about our potential to overcome therapy resistance, which remains one of the biggest challenges in cancer care. In addition, we are very excited about the modular nature of our payloads, which allows them to be compatible with various targeted delivery methods, enabling the generation of numerous new medicines. Q: What advice do you have for other biotech companies just getting started? A: My advice is simple: don’t be afraid to ask for help. Building a biotech startup involves navigating so many complex challenges, especially for first-time founders, and it can feel overwhelming. When I first started, I wasn’t sure where to begin or if my idea was even feasible. But by reaching out for help, even through cold outreach, I met incredible mentors who shared their knowledge and opened doors to great opportunities. Their support has been instrumental in getting RedPoint off the ground. I think we often hesitate to ask for help because we fear rejection, but I’ve found there are so many people willing to help, even if you’ve never met them before—you just have to ask. Q: What has been most impactful or surprising to you since joining the MassBioDrive program? A: The most impactful part would be the tremendous support system and mentorship I received from the MassBioDrive (MBD) program. I think MBD is different from many other accelerator programs as it is tailored to each of our specific needs. From building the mentor team to covering biotech-specific topics, the program offers personalized guidance. Our mentors are incredibly knowledgeable and have been so supportive throughout the process. Each week, we engage in open discussions and receive constructive feedback on our progress. I’m truly grateful for the experience! Learn more about RedPoint Oncology: https://lnkd.in/eeQTDCh6 Learn more about MassBioDrive: https://lnkd.in/eAztxEdd Mengdie Wang, PhD

30

6 Comments

Join the ABCT: Accelerator for Biosciences in Connecticut team and Women In Bio - Engage. Educate. Empower. on October 8th for a #networking mixer! 🔗 - https://lu.ma/ABCTWIB Connect with fellow life sciences companies, entrepreneurs and business leaders during a mixer created for bioscience professionals. Learn more about the companies in your area and build important connections with industry leaders! #Biosciences #startup #entrepreneurs

8

🎯 Start Your Day at the Antibody Therapeutics Xchange with Rachel Fong! 🎯 We're excited to kick off the Antibody Therapeutics Xchange - Maryland 2024 with an insightful Opening Address & Keynote Presentation by Rachel Fong, Director of Strategic Partnerships at Integral Molecular. 🌟 ✨ REGISTER NOW and get your Complimentary Pass! https://lnkd.in/eqvCJ5MG 📅 Date: Monday, 28 October 2024 ⏰ Time: 08:30 AM - 09:00 AM 📍 Location: Marriott College Park, Maryland 💡 What to Expect: 🔬 Learn how cell-based protein arrays like the Membrane Proteome Array (MPA) are transforming antibody specificity testing. ⚙️ Understand the impact of off-target binding and how it contributes to drug attrition and patient risks. 🧪 Rachel Fong with over 10 years at Integral Molecular, has been a key player in launching the MPA platform and managing high-impact collaborations. As a co-author of over a dozen publications, she brings an expert perspective on guiding projects from concept to success. Don't miss this chance to dive deep into cutting-edge solutions that are shaping the future of antibody-based therapies! 🌍🔗 💊Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. #AntibodyTherapeutics #Biotech #Pharma #DrugDevelopment #AntibodyEngineering #Polyspecificity #IntegralMolecular #MembraneProteomeArray #AntibodySpecificity #TherapeuticInnovation #PharmaceuticalResearch #Biopharma #AntibodyDiscovery #MPATechnology #BiotechnologyEvent #TherapeuticDevelopment #ClinicalResearch #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

8

We’re excited to announce that Maria I. Florez, Senior Consultant at Tufts Center for the Study of Drug Development, will be chairing the upcoming PCTO Summit in Boston! 🎉 Don’t miss this opportunity to gain insights from industry leaders and connect with professionals advancing clinical research! 🌟 #PrecisionEvolutionGlobal #Events #Summits #Conferences #Oncology #ClinicalTrials #BiopharmaLeadership #InnovationInTrials #LifeSciences #FutureOfClinicalResearch

7

Join us December 10-12 at the 7th Annual RNA-Targeted Drug Discovery & Development Summit in our home city of Boston! We can't wait to explore the latest and greatest in RNA-targeting therapeutics with experts and innovators from across the RNA world.      If that includes you, we'd love to connect and discuss how the Momentum team can accelerate your drug discovery and development project. We have experience working with RNA targets across a wide range of analytical services and can provide customized assay solutions to best tackle your specific research challenges.      On Wednesday, December 11th at 2:30PM, our CEO & Founder Can Ozbal will present "A Complete Workflow for the Identification and Characterization of Small Molecule Modulators of RNA." This talk will describe an end-to-end strategy that can be used to discover, validate, and characterize potent and specific RNA-targeting small-molecule drugs, including covalent drugs.      To schedule a time to meet with the Momentum team at the 7th Annual RNA-Targeted Drug Discovery & Development Summit, send us a message at: https://lnkd.in/dSD6dHDZ     Or, to learn more about the conference, visit: https://lnkd.in/gzcGvHH     #RNADrugDIscovery #RNAResearch #RNA   

11

In my biggest outside voice: PHILLY, ARE YOU READY TO SHOW UP AND SHOW OUT AT BIO!? We are representing the BEST LIFE SCIENCE ECOSYSTEM in the world! We are gonna let everyone know if you are not sciencing HERE, you are NOWHERE! When we get done speaking with these companies/people, they’re gonna go home, pack their bags, and move their science to Philly! #lifescienceindustry #lifesciences #lifescience -In Philly, Science is a VERB! https://lnkd.in/eGA_MMdA

68

5 Comments

Kevin King, BioIVT’s Senior Director of #Donor Center Strategy and Growth will be providing his industry insight and expertise by moderating a roundtable session at the 2nd Annual Donor Selection & Source Summit today entitled “Mitigating Risks in #CellandGeneTherapy: Re-evaluating Donor Selection and Characterizing Cellular Starting Material". The discussion will include topics like: • Establishing industry standard criteria for donor eligibility and implementation of advanced screening technologies. • Characterization of cellular properties and standardized assays to assess donor derived cell quality and function. As experts in providing RUO & GMP cellular starting and ancillary materials for the manufacture of #AdvancedTherapies, our aim is to foster collaboration between stakeholders to share needs as well as provide input on implementing risk mitigation strategies and foresight for sourcing donor-derived cellular starting material. Make sure to connect with Kevin and Lisa Kretzschmar, MBA if you will be at the event. If you are not attending the event, you can contact our experts here: https://hubs.ly/Q02Ywbkk0 Or view a recording of one of our previous expert roundtables here: https://hubs.ly/Q02Yw96w0 And access other insightful reference materials here: https://hubs.ly/Q02Ywf510) #CellTherapy #GeneTherapy #ATMPs

19

#Cancer remains a major public health challenge, and monitoring the effectiveness of treatments is key to advancing care. 🤝 Isogenica's collaboration on three projects with Frederick National Laboratory for Cancer Research developed VHH-based diagnostics to aid in this crucial process. This partnership supports FNLCR's mission to improve cancer treatment and monitoring, identifying what's truly working in immuno-oncology. 🔗 Want to know more about this collaboration? Read the press release here: https://loom.ly/KAJ5fY4 #CancerResearch #Biomarkers #Oncology

12

A Curative Solution: How Cell & Gene Therapies Support Patients & NJ’s Life Sciences Industry https://ow.ly/xOPe50UnvNc #CellTherapy #GeneTherapy #LifeSciences #Biotech #HealthcareInnovation #PatientCare #NewJerseyLifeSciences

2

SFA Therapeutics: From Temple Research to Revolutionizing Autoimmune Therapies Check out our latest BioBuzz story on SFA Therapeutics, a biotech company based in Jenkintown, PA, making strides in autoimmune and chronic inflammatory disease treatments. Born from a dinner conversation between Dr. Ira Spector, Dr. Mark Feitelson, and Dr. Alla Arzumanyan, SFA is now developing cutting-edge oral therapies backed by groundbreaking microbiome research from Temple University.

7